Technologieangebote

Immunotherapy with Tumour-Associated Antigens Derived from PAX2 and PAX8

Immunogenic T-cell epitopes from PAX2 and PAX8 have been found as promising immunotherapy against renal, colorectal, breast and ovarian cancer.

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Ursula Haufe

Kommentare (0)

Schreiben Sie einen Kommentar